An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
收藏DataCite Commons2026-01-28 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012696/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to find out whether Nivolumab will significantly improve overall survival as compared to therapy of investigator's choice in patients with recurrent or metastatic head and neck carcinoma.
提供机构：
Vivli
创建时间：
2026-01-28
